



NEWS RELEASE

For Further Information Contact:

Roy Wolvin
Nymox Pharmaceutical Corporation
1-800-93NYMOX
www.nymox.com

For Immediate Release:

Nymox NXC-4720 Reduces E. Coli Contamination By 99%

HASBROUCK HEIGHTS, NJ (December 12, 2006) Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is developing NXC-4720, the Company's innovative new product targeting *E. coli* O157:H7 food poisoning at its source: the contamination of food products. Studies have shown that NXC-4720 is capable of reducing the level of *E. coli* O157:H7 contamination by over 99%.

Recent outbreaks of *E. coli* O157:H7 food poisoning highlight the vulnerability of the U.S. food supply chain and food industry to this serious public health hazard. As of December 10, 2006, 61 persons in northeastern U.S. had reported sick as a result of *E. coli* O157:H7 food poisoning with 50 requiring hospitalization. Preliminary results point to contamination of green onions. An earlier outbreak of *E. coli* O157:H7 contamination of fresh spinach in September 2006 left three people dead and over 100 people hospitalized. Children and the elderly are particularly at risk for the effects of this serious illness.

Nymox has patent rights covering novel treatments for *E. coli* contamination and infection as well as other anti-bacterial treatments, including three issued U.S. patents, other international versions of these patents, as well as numerous pending patent applications both in the U.S. and abroad.

Despite efforts to improve the safety of the food supply system, outbreaks of potentially deadly *E. coli* O157 food contamination remain common, both in the U.S. and around the world, including England, Ireland, France, and Canada. The Centers for Disease Control (CDC) estimates that *E. coli* O157 infections cause 73,000 illnesses annually in the U.S. alone, resulting in more than 2,000 hospitalizations and 60 deaths. A recent study by the U.S. Department of Agriculture estimated that the annual cost of illness due to *E. coli* O157 was \$404 million, including \$370 million for premature deaths: Frenzen PD et al, *Journal of Food Protection* 2005; 68:2623-2630.

More information about Nymox is available at www.nymox.com, email: info@nymox.com, or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.